Tag: progression-free survival

1. Idecabtagene vicleucel treatment showed substantial antitumor activity in the majority of pre-treated patients with refractory and relapsed myeloma. 2. Almost all patients had grade 3 or 4 adverse events, which included myelosuppression and cytokine release syndrome. Evidence Rating Level: 2 (Good) Study Rundown: Multiple myeloma patients who progressed on proteasome inhibitors,...